CED delivery of abEC1.1 further validated the feasibility of direct antibody administration to GBM [104], achieving significant reductions in tumor area, Gfap expression [101], and PH3 levels [105], complementing other proliferation markers such as Ki-67 [102]. This evidence concerns the gene MKI67 and glioblastoma.